Search Medical Condition
Please enter condition
Please choose location

Glan, St. Veit Clinical Trials

A listing of Glan, St. Veit clinical trials actively recruiting patients volunteers.

RESULTS

Found (13) clinical trials

Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer

Phase 1 (n=9-12) As fulvestrant and AZD5363 have not previously been administered to this population, we have incorporated an initial phase I dose escalation: - 3 patients will receive fulvestrant 500mg on day 1 and 400mg AZD5363 oral capsules or tablets bd 4 days on and 3 days off. They ...

Phase

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer.

Patients will be randomised in 1:1 ratio to either olaparib or placebo. Randomisation will be stratified by Hormone receptor status (ER and/or PgR positive/HER2 negative versus TNBC), prior neoadjuvant versus adjuvant chemotherapy and prior platinum use for breast cancer. Randomised patients will receive study treatment for up to a maximum ...

Phase

A Long-term Active Treatment Study of Mongersen (GED-0301) in Subjects With Crohn's Disease

This is a long-term active treatment study in patients with Crohn's disease (CD). Subjects who met the early escape criteria in Study GED-0301-CD-002, or subjects who completed Study GED-0301-002 or GED-0301-003, may be eligible for this study. Primary objective is to assess long-term safety of GED 0301. Additional efficacy and ...

Phase

Tissue Sample Collection From Patients With Soft Tissue Sarcoma of the Arms Hands Legs or Feet Treated on Clinial Trial CRUK-VORTEX

OBJECTIVES: - Determine early in the course of treatment which patients treated on clinical trial CRUK-VORTEX have an increased likelihood of distant metastases so as to highlight individuals who might benefit from early adjuvant systemic therapy. OUTLINE: This is a multicenter study. Tumour and normal tissue samples will be taken ...

Phase N/A

CA 125 Levels in Treating Patients With Relapsed Advanced Ovarian Cancer Fallopian Tube Cancer or Primary Peritoneal Cancer Who Are Receiving Tamoxifen

OBJECTIVES: - Determine the percentage of patients with relapsed advanced ovarian carcinoma, fallopian tube carcinoma, or primary peritoneal carcinoma who have a log linear rise in CA 125 levels. - Determine whether the log linear part of the curve is consistent enough to allow comparison of the slope before and ...

Phase